Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study

The oncological outcome after lung metastasis in patients with chondrosarcoma of the extremities has not been reported. Between June 2000 and June 2013, 179 patients with chondrosarcoma in the extremities were treated at eleven hospitals. Twenty consecutive patients (11.2%) developed lung metastases...

Full description

Bibliographic Details
Main Authors:	Nakamura, Tomoki, Matsumine, Akihiko, Yamada, Satoshi, Tsukushi, Satoshi, Kawanami, Katsuhisa, Ohno, Takatoshi, Katagiri, Hirohisa, Sugiura, Hideshi, Yamada, Kenji, Yamada, Yoshihisa, Sudo, Akihiro, Nishida, Yoshihiro
Format:	Online
Language:	English
Published:	Dove Medical Press 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973757/

id	pubmed-4973757
recordtype	oai_dc
spelling	pubmed-49737572016-08-17 Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study Nakamura, Tomoki Matsumine, Akihiko Yamada, Satoshi Tsukushi, Satoshi Kawanami, Katsuhisa Ohno, Takatoshi Katagiri, Hirohisa Sugiura, Hideshi Yamada, Kenji Yamada, Yoshihisa Sudo, Akihiro Nishida, Yoshihiro Original Research The oncological outcome after lung metastasis in patients with chondrosarcoma of the extremities has not been reported. Between June 2000 and June 2013, 179 patients with chondrosarcoma in the extremities were treated at eleven hospitals. Twenty consecutive patients (11.2%) developed lung metastases after initial treatment of primary chondrosarcoma in the extremities. We investigated the oncological outcome of 20 chondrosarcoma patients with lung metastasis. There were 14 males and six females with a mean age of 49 years. The mean duration between primary surgery and appearance of lung metastases was 34 months. The mean follow-up period was 48 months. We excluded patients with lung metastasis at the time of presentation from this study. At the final follow-up, four of 20 patients had no evidence of disease, four were alive with disease, and twelve had died of disease. The 3- and 5-year survival rates after lung metastasis were 51.5% and 45.7%, respectively. Tumor grade, extrapulmonary metastasis, and treatment for lung metastases including metastasectomy and radiofrequency ablation were identified by univariate analysis to be significant prognostic factors for oncological analysis. In conclusion, this study evaluated the oncological outcome in patients with chondrosarcoma of the extremities with lung metastasis. Although a large-scale study might be required to confirm the results of this study, we suggest that metastasectomy and/or radiofrequency ablation should be considered to improve postmetastatic survival. Dove Medical Press 2016-07-29 /pmc/articles/PMC4973757/ /pubmed/27536136 http://dx.doi.org/10.2147/OTT.S107638 Text en © 2016 Nakamura et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Nakamura, Tomoki Matsumine, Akihiko Yamada, Satoshi Tsukushi, Satoshi Kawanami, Katsuhisa Ohno, Takatoshi Katagiri, Hirohisa Sugiura, Hideshi Yamada, Kenji Yamada, Yoshihisa Sudo, Akihiro Nishida, Yoshihiro
spellingShingle	Nakamura, Tomoki Matsumine, Akihiko Yamada, Satoshi Tsukushi, Satoshi Kawanami, Katsuhisa Ohno, Takatoshi Katagiri, Hirohisa Sugiura, Hideshi Yamada, Kenji Yamada, Yoshihisa Sudo, Akihiro Nishida, Yoshihiro Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study
author_facet	Nakamura, Tomoki Matsumine, Akihiko Yamada, Satoshi Tsukushi, Satoshi Kawanami, Katsuhisa Ohno, Takatoshi Katagiri, Hirohisa Sugiura, Hideshi Yamada, Kenji Yamada, Yoshihisa Sudo, Akihiro Nishida, Yoshihiro
author_sort	Nakamura, Tomoki
title	Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study
title_short	Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study
title_full	Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study
title_fullStr	Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study
title_full_unstemmed	Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study
title_sort	oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: tokai musculoskeletal oncology consortium study
description	The oncological outcome after lung metastasis in patients with chondrosarcoma of the extremities has not been reported. Between June 2000 and June 2013, 179 patients with chondrosarcoma in the extremities were treated at eleven hospitals. Twenty consecutive patients (11.2%) developed lung metastases after initial treatment of primary chondrosarcoma in the extremities. We investigated the oncological outcome of 20 chondrosarcoma patients with lung metastasis. There were 14 males and six females with a mean age of 49 years. The mean duration between primary surgery and appearance of lung metastases was 34 months. The mean follow-up period was 48 months. We excluded patients with lung metastasis at the time of presentation from this study. At the final follow-up, four of 20 patients had no evidence of disease, four were alive with disease, and twelve had died of disease. The 3- and 5-year survival rates after lung metastasis were 51.5% and 45.7%, respectively. Tumor grade, extrapulmonary metastasis, and treatment for lung metastases including metastasectomy and radiofrequency ablation were identified by univariate analysis to be significant prognostic factors for oncological analysis. In conclusion, this study evaluated the oncological outcome in patients with chondrosarcoma of the extremities with lung metastasis. Although a large-scale study might be required to confirm the results of this study, we suggest that metastasectomy and/or radiofrequency ablation should be considered to improve postmetastatic survival.
publisher	Dove Medical Press
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973757/
_version_	1613621513545580544

Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study

Similar Items